The short version of CJC-1295 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-08-17. Anything still debated is marked as such rather than presented as settled.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | Built on a 29 residue sequence |
| Primary target | GHRH receptor (GHRHR) | Class B G protein coupled receptor |
| Unconjugated half life | Minutes | Limited by protease degradation |
| Key modification | Four residue substitutions | Positions 2, 8, 15 and 27 |
| Common synonym | Modified GRF(1-29) | Usually denotes the form without DAC |
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
=== Receptors === Innate immune system senses intact peptidoglycan and peptidoglycan fragments using numerous PRRs (pattern recognition receptors) that are secreted, expressed intracellularly or expressed on the cell surface.
Isolated cataplexy unto itself (i.e., in the absence of characteristically associated narcolepsy), admittedly a rare condition There is anecdotal and tentative, as-yet-undocumented information suggesting that clomipramine may address certain core features of hyperacusis, and possibly misophonia. In the case of hyperacusis, this appears to be especially the case at doses > 150 mg/d. As-with obsessive-compulsive disorder, a full response to any one dose may not be experienced for up to 12–16 weeks. Although lithium is most-associated with the treatment of bipolar disorder (where it is known for its general mood-stabilising features and to be especially useful in treating and preventing mania), it may have a certain place in the management of treatment-resistant depression (which is often of higher severity than other depressions which have not been addressed with ECT). In these cases it is often prescribed alongside SSRIs (e.g., fluoxetine, paroxetine), venlafaxine and various of the tricyclics (e.g., clomipramine, amitriptyline, nortriptyline, maprotiline), which is why it may feature sometimes in the discussion of depression being managed with clomipramine. Lithium also significantly reduces the long-term risk of suicide in general. In any case, it is not necessary to have a diagnosis of bipolar affective disorder (manic-depressive illness), or even to be considered to have subtle elements of it ("soft bipolarity"), to benefit from lithium in the context of treatment with clomipramine.
Metofoline (INN), also known as methofoline (USAN), is an opioid analgesic drug discovered in the 1950s by a team of Swiss researchers at Hoffmann-La Roche. Methopholine is an isoquinoline derivative which is not structurally related to most other opioids. However, its structural similarity to the non-opioid alkaloid papaverine is notable. Metofoline has around the same efficacy as an analgesic as codeine, and was evaluated for the treatment of postoperative pain. Metofoline tablets were marketed in the United States under the brand name of Versidyne, but the drug was withdrawn from the market in 1965 due to the occurrence of ophthalmic side-effects alongside the discovery that the drug could produce cataracts in dogs. Metofoline has two enantiomers, with the levo (R) enantiomer being the active form, around 3x the potency of codeine, and the (S) enantiomer being inactive. Analogs where the 4'-chloro group has been replaced by other electron withdrawing groups have also been tested, the fluoro derivative being slightly more potent than chloro, and the nitro derivative being most potent of all, with the racemic 4'-nitromethopholine being around 20x the potency of codeine. Later research was carried out by Bristol-Myer in the 1960s and animal studies suggested derivatives with significantly increased analgesic activity of over x50 codeine.
== Myths == Some popular beliefs attached to weight loss have been shown to either have less effect on weight loss than commonly believed or are actively unhealthy. According to Harvard Health, the idea of metabolic rate being the "key to weight" is "part truth and part myth" as while metabolism does affect weight loss, external forces such as diet and exercise have an equal effect. They also commented that the idea of changing one's rate of metabolism is under debate. Diet plans in fitness magazines are also often believed to be effective but may actually be harmful by limiting the daily intake of important calories and nutrients which can be detrimental depending on the person and are even capable of driving individuals away from weight loss.
== Uses == P. rubens is the source of β-lactam antibiotics, principally of penicillins and to a lesser extent, cephalosporins. The species produces three penicillins, benzylpenicillin (G), phenoxymethylpenicillin (V) and octanoylpenicillin (K). Penicillin G is a naturally occurring compound that was first isolated and used as an antibiotic. Penicillins from P. rubens are effective against Gram-positive bacteria such as the species of Bacillus, Clostridium, Corynebacterium, Pneumococcus, Streptococcus, and Staphylococcus. They are clinically used to treat actinomycosis, anthrax, botulism, clostridial infections, diphtheria, empyema, endocarditis, food poisoning (due to Listeria), gas gangrene, meningitis, pneumonia, pericarditis, septicaemia, and syphilis. However, they are useless against Gram-negative bacteria since these bacteria are impermeable to the compounds because of their additional outer cell membrane, as well as some species producing pencillases (β-lactamases) that destroy the penicillin structure (β-lactam ring). However, semisynthetic penicillins like aminopenicillins (ampicillin, amoxicillin, and bacampicillin), carboxypenicillins (carbenicillin and ticarcillin) and ureidopenicillins (mezlocillin, azlocillin, and piperacillin) have been developed that are effective against these bacteria. Cephalosporins, naturally produced by other fungi belonging to the genus Acremonium, are one of the most widely used antibiotics by clinicians and is also produced by P. rubens. However, they are not naturally produced by P. rubens.
Sources: en.wikipedia.org
Prior to the US naval deployment, Richard Grenell, Trump's special envoy to Venezuela, had been working towards a deal with Maduro's administration. After extended talks, Maduro's aides had reportedly offered American companies preference in contracts and access to all oil and gold ventures within the country, and to sharply reduce export ties with China, Iran, and Russia. Maduro knew that "loosening those alliances was an inevitable price for avoiding American military intervention", a source told The New York Times. Some concessions were made as talks continued; in May 2025, Venezuela agreed to release Joseph St. Clair, a US Air Force veteran who had been "wrongfully detained" by Venezuelan security forces, according to the US State Department. Chevron's license to operate in Venezuela under US sanctions, revoked by Trump in February, was reinstated in July 2025. Preliminary efforts to allow Shell to restart work in Venezuela also began. Rubio strongly opposed Grenell's "resource diplomacy" approach, stating that "Chevron's continued operations in Venezuela legitimize and enable Maduro's grip on power". On 6 October, Trump directed Grenell to shut down all diplomatic talks with Venezuela amid growing tensions and frustrations with Venezuelan political dialogue. Since at least April 2025, Qatar had acted as a political go-between, attempting to maintain communications between the two nations through back-channel diplomacy.
The shape of the ribosomal tunnel is irregular, and its size varies depending on the organism and cell type. Ribosomal tunnels in bacteria are generally longer and wider than those in the ribosomes of higher organisms. In bacteria, the tunnel length is approximately 9.2 nm, while in eukaryotes it is about 8.3 nm and the average radius of the ribosomal tunnel is on average 0.57 nm in bacteria and 0.51 nm in eukaryotes. The tunnel can accommodate a polypeptide consisting of around 40 to 60 amino acid residues. The tunnel walls are composed of rRNA and several ribosomal proteins. The tunnel is filled with water and ions, while small molecules such as ornithine may diffuse into it. The tunnel contains a constriction formed by loops of ribosomal proteins uL4 and uL22, which divide the tunnel space into an inner and an outer part (sometimes also referred to as the upper and lower parts). The inner portion near the catalytic site is approximately 3.5 nm long and accommodates a nascent polypeptide of 12 to 16 amino acid residues. There is a second constriction in the ribosomes of some eukaryotes that has implications for the regulation of short peptide synthesis. The outer part of the tunnel widens toward its opening and forms the so-called vestibule. The opening of the tunnel is flanked by the ribosomal proteins uL23, uL24, uL29 and uL32. In eukaryotes, also uL35, uL39e, or uL25. Ribosome-associated protein biogenesis factors such as the trigger factor or peptide deformylase bind to their vicinity.
CRF, produced in the PVN, activates CRF1 receptors and CRF2 receptors distributed across limbic circuits. CRF1 receptor activation, which mediates rapid and intense stress responses, triggers acute dynorphin release in limbic stress-responsive regions including the NAcc, basolateral amygdala, dorsal raphe nucleus (DRN), hippocampus, and bed nucleus of the stria terminalis (BNST). CRF2 receptor activation, generally associated with slower, later-phase stress response components, also induces dynorphin-dependent aversive responses such as conditioned place aversion (CPA). Subsequently dynorphin activates KORs expressed on GABAergic and dopaminergic neurons, encoding the aversive and dysphoric qualities of stress exposure. Acutely stress-induced dynorphin release and KOR activation have evolutionarily adaptive functions. KOR-mediated analgesia facilitates physical escape responses to threat, and concurrent KOR-induced dysphoria and aversion promote avoidance and active coping. However, during the delayed temporal phase following acute stress exposure (hours to days), stress-induced KOR signaling initiates intracellular signaling cascades including p38 MAPK and extracellular signal-regulated kinases (ERK) which phosphorylate transcription factors such as cAMP response element-binding protein (CREB) and alter dynorphin and KOR gene expression itself, establishing a self-amplifying cycle.
Metofoline (INN), also known as methofoline (USAN), is an opioid analgesic drug discovered in the 1950s by a team of Swiss researchers at Hoffmann-La Roche. Methopholine is an isoquinoline derivative which is not structurally related to most other opioids. However, its structural similarity to the non-opioid alkaloid papaverine is notable. Metofoline has around the same efficacy as an analgesic as codeine, and was evaluated for the treatment of postoperative pain. Metofoline tablets were marketed in the United States under the brand name of Versidyne, but the drug was withdrawn from the market in 1965 due to the occurrence of ophthalmic side-effects alongside the discovery that the drug could produce cataracts in dogs. Metofoline has two enantiomers, with the levo (R) enantiomer being the active form, around 3x the potency of codeine, and the (S) enantiomer being inactive. Analogs where the 4'-chloro group has been replaced by other electron withdrawing groups have also been tested, the fluoro derivative being slightly more potent than chloro, and the nitro derivative being most potent of all, with the racemic 4'-nitromethopholine being around 20x the potency of codeine. Later research was carried out by Bristol-Myer in the 1960s and animal studies suggested derivatives with significantly increased analgesic activity of over x50 codeine.
Sources: en.wikipedia.org
This work hinged on his demonstration that red blood cell glutathione was unstable to oxidative stress. Later, he was to develop an assay for glutathione that was widely used in studies of red cell oxidative metabolism. He was later transferred to Camp Detrick in Frederick, Maryland (1954–1955), where he studied Q fever. He was honorably discharged from the Army with the rank of captain. Beutler then joined the faculty of the Department of Medicine at the University of Chicago, where he studied iron metabolism and red blood cell metabolism. In 1959, he became chairman of the Department of Medicine of the City of Hope National Medical Center in Duarte, California, and in 1979 assumed the chairmanship of the Department of Clinical Research at the Scripps Clinic and Research Foundation. Three years later, he was asked to become Chairman of a merged department (the Department of Molecular and Experimental Medicine) at Scripps, which later became The Scripps Research Institute in La Jolla, CA. He maintained his position as Chairman until his 80th birthday, only a few days before his death. Not long after moving to California, Beutler made one of his most important contributions. A new colleague at the City of Hope and ultimately a lifelong friend, Susumu Ohno had recently demonstrated that the histologically observable Barr body present in the nuclei of mammalian female cells was a hyperchromatic X chromosome. Beutler immediately recognized that this might account for the variable expression of X-linked genes in females heterozygous for X-linked mutations.
=== Physiological === Depending on the length of drug use, there is a chance that the immune system can be damaged. Most of these side-effects are dose-dependent, the most common being elevated blood pressure, especially in those with pre-existing hypertension. In addition to morphological changes of the heart which may have a permanent adverse effect on cardiovascular efficiency. AAS have been shown to alter fasting blood sugar and glucose tolerance tests. AAS such as testosterone also increase the risk of cardiovascular disease or coronary artery disease. Acne is fairly common among AAS users, mostly due to stimulation of the sebaceous glands by increased testosterone levels. Conversion of testosterone to DHT can accelerate the rate of premature baldness for males genetically predisposed, but testosterone itself can produce baldness in females. A number of severe side effects can occur if adolescents use AAS. For example, AAS may prematurely stop the lengthening of bones (premature epiphyseal fusion through increased levels of estrogen metabolites), resulting in stunted growth. Other effects include, but are not limited to, accelerated bone maturation, increased frequency and duration of erections, and premature sexual development. AAS use in adolescence is also correlated with poorer attitudes related to health.
=== Aneuploidy === Sex chromosomes Analysis of maternal serum cffDNA by high-throughput sequencing can detect common fetal sex chromosome aneuploidies such as Turner's syndrome, Klinefelter's syndrome and triple X syndrome but the procedure's positive predictive value is low.
Sources: en.wikipedia.org
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.
DAC stands for drug affinity complex, a term describing the maleimidopropionic acid linker. This group forms a covalent bond with the cysteine residue on serum albumin after administration. The resulting adduct is what extends the circulating half life from minutes to days.
No. It is entirely synthetic and does not correspond to any known endogenous peptide. The design starts from human growth hormone releasing hormone and introduces deliberate substitutions. Any biological effect comes from mimicking the natural hormone at its receptor.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.